Atabak Mokari Corcept Therapeutics Inc (CORT) insider trading activity

Atabak Mokari is Chief Financial Officer of CORCEPT THERAPEUTICS INC. Currently has a direct ownership of 14,559 shares of CORT, which is worth approximately $1.1 Million. The most recent transaction as insider was on Dec 02, 2025, when has been sold 118 shares (Common Stock) at a price of $79.78 per share, resulting in proceeds of $9,414. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 14.6K

1.66% 3M change

18.02% 12M change

Total Value Held $1.1 Million

Atabak Mokari Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 02 2025	SELL Payment of exercise price or tax liability	$9,414 $79.78 p/Share	118 Reduced 0.8%	14,559 Common Stock
Dec 01 2025	BUY Grant, award, or other acquisition	$14,200 $39.89 p/Share	356 Added 2.37%	14,677 Common Stock
Sep 03 2025	SELL Payment of exercise price or tax liability	$10,278 $71.38 p/Share	144 Reduced 1.0%	14,321 Common Stock
Sep 02 2025	BUY Grant, award, or other acquisition	$14,276 $35.69 p/Share	400 Added 2.69%	14,465 Common Stock
Jun 03 2025	SELL Payment of exercise price or tax liability	$37,201 $71.68 p/Share	519 Reduced 3.56%	14,065 Common Stock
Jun 02 2025	BUY Grant, award, or other acquisition	$55,552 $35.84 p/Share	1,550 Added 9.61%	14,584 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$13,812 $60.58 p/Share	228 Reduced 1.78%	12,570 Common Stock

Mar 03 2025	BUY Grant, award, or other acquisition	$13,706 $29.54 p/Share	464 Added 3.44%	13,034 Common Stock
Dec 02 2024	SELL Payment of exercise price or tax liability	$10,497 $57.68 p/Share	182 Reduced 1.45%	12,336 Common Stock
Dec 02 2024	BUY Grant, award, or other acquisition	$13,679 $29.61 p/Share	462 Added 3.48%	12,798 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$5,047 $35.3 p/Share	143 Reduced 1.21%	11,718 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	$13,704 $17.13 p/Share	800 Added 6.01%	12,518 Common Stock
Jun 03 2024	SELL Payment of exercise price or tax liability	$17,227 $30.17 p/Share	571 Reduced 5.99%	8,965 Common Stock
Jun 03 2024	BUY Grant, award, or other acquisition	$45,322 $15.65 p/Share	2,896 Added 19.62%	11,861 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$12,439 $24.06 p/Share	517 Reduced 5.78%	8,428 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	$13,329 $12.03 p/Share	1,108 Added 10.41%	9,536 Common Stock
Dec 01 2023	BUY Grant, award, or other acquisition	$13,197 $12.99 p/Share	1,016 Added 10.2%	8,945 Common Stock
Sep 01 2023	BUY Grant, award, or other acquisition	$13,173 $16.55 p/Share	796 Added 8.84%	8,204 Common Stock
Jun 01 2023	BUY Grant, award, or other acquisition	$37,939 $11.49 p/Share	3,302 Added 30.83%	7,408 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	$25,023 $9.93 p/Share	2,520 Added 38.03%	4,106 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	$20,602 $12.99 p/Share	1,586 Added 50.0%	1,586 Common Stock

Atabak Mokari

Chief Financial Officer

Menlo Park, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CORT shares.

Notify only if

Value

Insider Trading

Get notified when an Corcept Therapeutics Inc insider buys or sells CORT shares.

Notify only if

Operation

Value

Type

News

Receive news related to CORCEPT THERAPEUTICS INC

Track Activities on CORT

Account